TrialThoracic cancer2019

Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303.

Xiaoyan Si et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.